 Home > Medical News > Medicines Company News > AACR 2021 | Baiji Shenzhou, Corning Jerry, Tianji Bio and other Chinese companies will appear

AACR 2021 | Baiji Shenzhou, Corning Jerry, Tianji Bio and other Chinese companies will appear

 Last Update: 2021-03-25
 Source: Internet
 Author: User

Tags

single edge safety razor

natural antibodies

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

(AACR)，。，AACR。，2021AACR（）410-15517-21。，AACR，（）。

1、：、sitravatinib、ociperlimab

：PD-1、、TIGIT

，PD-1（）、sitravatinib，TIGITociperlimab（BGB-A1217）。

lgG4PD-1，3，NSCLC、、。，RATIONALE 3033， NSCLC 。

，202011，RATIONALE 303（OS），，。，CDERATIONALE 303NSCLC，6。

Sitravatinib，（RTKs），Mirati Therapeutics（）、。，sitravatinib：sitravatinib（PROC）/；sitravatinibPD-1/PD-L1/1b。

2、：KN046

：PD-L1/CTLA-4

KN046PD-L1CTLA-4，T，。，KN046CTLA-4PD-L1，PD-L1Treg。

At this conference, Corning Jerry will announce the data of an open, multi-center Phase 1b/2 clinical study (study number: KN046-203) of KN046 combined with paclitaxel in the treatment of patients with advanced triple-negative breast cancer in the form of a poster.

Phase 2 clinical interim data showed that the patient’s median PFS (Progressive Free Survival) was 7.

Mechanism of action: CD73 antibody

Uliledlimab is a highly differentiated CD73 humanized monoclonal antibody.

At this conference, Tianjing Bio will display the new protein structure of uliledlimab and CD73, as well as a series of preclinical data when it is used as a single agent and PD-1/PD-L1 antibody.

Research believes that: TJD5 is a humanized anti-CD73 antibody with a unique C-terminal domain epitope, which can realize a new dimer binding mode in vivo, which distinguishes it from other CD73 antibodies in terms of mechanism of action and inhibitory efficacy.

Mechanism of action: c-Myc targeted therapy

c-Myc is an oncogenic transcription factor, which plays a major role in tumorigenesis, cancer cell survival, proliferation and immune escape.

At this AACR annual meeting, Pioneer Pharmaceuticals will publish the results of a preclinical study of GT19077 and GT19506 for c-Myc-driven blood cancer and small cell lung cancer (SCLC).

Mechanism of action: focal adhesion kinase (FAK) inhibitor, FLT3 inhibitor/BCL-2 inhibitor, IAP inhibitor, etc.

APG-2449 is a new type of FAK/ALK/ROS1 inhibitor with high oral bioavailability under development by Yasheng Pharmaceutical.

The other is a study on the synergy of FLT3 inhibitor auribatinib (HQP1351) and BCL-2 selective inhibitor APG-2575 in a preclinical model of FLT3 mutant AML.

In addition, researchers will also share the results of the therapeutic potential of IAP inhibitor APG-1387 combined with DR5 agonist CTB-006 in preclinical models of solid tumors.
The results showed that in vitro, the combination therapy showed a dose-dependent synergistic effect in various cancer cell lines.
In the MDA-MB-231 and 2LMP TNBC xenograft models, APG-1387 or CTB-006 single drugs show limited anti-tumor activity, and the combination of the two can enhance this effect.

6.
Qiyu Bio: QP34563457

Mechanism of action: trastuzumab/pertuzumab/IL-15 trifunctional fusion protein

IL-15 is a member of the IL-2 superfamily, and has similar biological activities as IL-2, and has the ability to stimulate the proliferation of T cells and natural killer (NK) cells.
HER2 is overexpressed in approximately 10% to 20% of breast cancers, and its expression is associated with a worse prognosis of patients.
At this AACR annual meeting, Qiyu Bio will announce the results of a preclinical evaluation study of the three-functional fusion protein QP34563457 for the treatment of HER2-positive cancer.

QP34563457 is a trastuzumab/pertuzumab/IL-15 trifunctional fusion protein developed by Qiyu Biologics using its bispecific antibody platform.
Trastuzumab (trastuzumab) and Pertuzumab (pertuzumab) are both HRE2 targeted therapy, among which Pertuzumab can inhibit HER2 receptor dimerization.
In vivo and in vitro studies have shown that the trifunctional fusion protein QP34563457 has higher biological activity than the HER2 antibody trastuzumab or pertuzumab and its combination, indicating that the candidate drug may have higher biological activity in HER2-positive cancers.
Good therapeutic potential.

7.
Jikai Pharmaceutical: B13.
14.
1 TCR-T, B8.
2.
4 TCR-T

Mechanism of action: TCR-T targeted therapy for RasG12V and RasG13D

RAS is the first oncogene identified in human tumors.
The currently known RAS family has three genes, KRAS, NRAS, and HRAS.
They are the most common oncogenes in cancer-about 20% of human tumors There is a RAS mutation.
Among them, KRAS mutations account for about 80% of the total RAS mutations, and the most common mutations are RasG12V and RasG13D.
However, no drug for RAS has been successfully developed and approved, and there are a large number of unmet medical needs in the treatment of cancers that carry RAS mutations.

At this AACR conference, Jikai Medicine will announce the results of a preclinical study using TCR to target the treatment of RAS mutant cancers.
In this study, the researchers developed two TCR-Ts through engineering modifications that can recognize RASG12V and RASG13D that appear on HLA-matched tumor cell lines, and induce strong INFγ release.
In addition, the researchers also observed effective and specific tumor cell lysis in multiple RASG12V and RASG13D tumor cell lines.
The researchers said that its TCR-T targeted therapy for RasG12V and RasG13D has great potential in the treatment of cancers driven by RAS mutations.

8.
Jiahe Bio: GB261, GB262, GB263, GB264

Mechanism of action: CD20/CD3 T cell adaptor, PD-L1/CD5 double antibody, etc.

According to the Jiahe Biologics press release, the pre-clinical progress of the company's four drug candidates on the dual antibody/triple antibody platform will be published at the AACR conference in 2021.
These studies are: 1) the new CD20/CD3 T cell engager (T cell engager) targeting CD20+ cancer has multiple mechanisms; 2) the new bispecific antibody targeting PD-L1 and CD55 for cancer treatment Development; 3) Application of cMET/cMET/EGFR trispecific antibody in the treatment of non-small cell lung cancer; 4) Claudin 18.
2/CD3 bispecific antibody can maintain effector function to develop better cancer therapy.

For more than 100 years, AACR has attracted researchers in this field with its scientific breadth and excellent reputation, promotes the exchange of new knowledge and new ideas among scientists in the field of cancer research, and provides training opportunities for the next generation of researchers to increase public awareness Cancer awareness.
We will continue to track the information of this AACR conference and share more cutting-edge developments in the field of cancer research with you.

Reference materials:

[1]AACR official website.
From https://#!/9325/

[2] Tianjing Bio will announce the mechanism of action and preclinical research data of its differentiated CD73 antibody Uliledlimab at the 2021 AACR (American Association for Cancer Research) annual meeting.
Retrieved Mar 11, 2021, from https:// -mabbiopharma.
com/cn/article-617.
aspx

[3] Corning Jerry will announce the clinical research data of PD-L1/CTLA-4 double antibody KN046 combined with paclitaxel in the treatment of triple-negative breast cancer at the AACR 2021 meeting.
Retrieved Mar 11, 2021, from http:// .
com/html/news/2281.
html

[4] BeiGene will announce a number of clinical and preclinical data at the American Association for Cancer Research (AACR) 2021 annual meeting.
Retrieved Mar 10, 2021, from https://ir.
beigene.
com/static-files/ 827d6c34-3ea5-4ad1-a1a3-62df61b03812

[5] Jiahe Biotech announced that it will announce the four latest preclinical progress at AACR 2021.
Retrieved Mar 11, 2021, from https:// -latest-preclinical-progress-to-be-presented-at-aacr-2021/

▽ attention [drug Mingkang Germany ] micro-channel public number

[Medical attention Mingkang Germany ] ] micro-channel public number

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.